These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 22104226)

  • 1. [Advances of heterogeneity of EGFR in non-small cell lung cancer].
    Zheng H; Zhang H; Shi H; Li B
    Zhongguo Fei Ai Za Zhi; 2011 Nov; 14(11):890-3. PubMed ID: 22104226
    [No Abstract]   [Full Text] [Related]  

  • 2. Clairvoyance or reliable prediction of the future?
    van Zandwijk N; van de Vijver MJ
    Ann Oncol; 2007 Mar; 18(3):407-8. PubMed ID: 17322538
    [No Abstract]   [Full Text] [Related]  

  • 3. Targeting CDC34 E2 ubiquitin conjugating enzyme for lung cancer therapy.
    Zhang S; Sun Y
    EBioMedicine; 2020 Apr; 54():102718. PubMed ID: 32268269
    [No Abstract]   [Full Text] [Related]  

  • 4. Third-generation EGFR-TKIs—a new hope for NSCLC.
    Akkermans R
    Lancet Respir Med; 2014 Jul; 2(7):520. PubMed ID: 25140365
    [No Abstract]   [Full Text] [Related]  

  • 5. [Studies and Progress of EGFR exon 20 Insertion Mutation in Non-small Cell Lung Cancer].
    Zhou W; Zhang W; Han B
    Zhongguo Fei Ai Za Zhi; 2020 Feb; 23(2):118-126. PubMed ID: 32093456
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Concomitant Genetic Alterations With Response to Treatment and Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With EGFR-Mutant Advanced Non-Small Cell Lung Cancer.
    Hong S; Gao F; Fu S; Wang Y; Fang W; Huang Y; Zhang L
    JAMA Oncol; 2018 May; 4(5):739-742. PubMed ID: 29596544
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of advanced EGFR-mutant NSCLC patients: Sequencing matters.
    Estevinho F; Felizardo M; Fernandes G; Figueiredo A; Lopes JA
    Pulmonology; 2019; 25(5):306-309. PubMed ID: 31182368
    [No Abstract]   [Full Text] [Related]  

  • 8. Afatinib in Osimertinib-Resistant EGFR ex19del/T790M/P794L Mutated NSCLC.
    van Kempen LC; Wang H; Aguirre ML; Spatz A; Kasymjanova G; Vilacha JF; Groves MR; Agulnik J; Small D
    J Thorac Oncol; 2018 Sep; 13(9):e161-e163. PubMed ID: 29704676
    [No Abstract]   [Full Text] [Related]  

  • 9. [Association between the epidermal growth receptor status and the efficacy of
 first-line chemotherapy in patients with advanced non-small cell lung cancer].
    Qin N; Zhang Q; Wang J; Zhang H; Gu Y; Yang X; Li X; Lv J; Wu Y; Nong J; Zhang X; Zhang S
    Zhongguo Fei Ai Za Zhi; 2015 Mar; 18(3):131-7. PubMed ID: 25800568
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Third generation EGFR TKI landscape for metastatic EGFR mutant non-small cell lung cancer (NSCLC).
    Tan AC; Teh YL; Lai GGY; Tan DSW
    Expert Rev Anticancer Ther; 2019 Jun; 19(6):431-435. PubMed ID: 30950666
    [No Abstract]   [Full Text] [Related]  

  • 11. Optimal management of patients with non-small cell lung cancer and epidermal growth factor receptor mutations.
    Lin CC; Yang JC
    Drugs; 2011 Jan; 71(1):79-88. PubMed ID: 21175241
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Computational platform for modelling, analysis, and prediction of anti-EGFR drug resistance for lung cancer.
    Yan H; Zhu GY; Wong M; Lee V
    Hong Kong Med J; 2019 Dec; 25 Suppl 9(6):40-42. PubMed ID: 31889035
    [No Abstract]   [Full Text] [Related]  

  • 13. EGFR mutations in non-small cell lung carcinomas may predict response to gefitinib: extension of an emerging paradigm.
    Chang KL; Lau SK
    Adv Anat Pathol; 2005 Mar; 12(2):47-52. PubMed ID: 15731572
    [No Abstract]   [Full Text] [Related]  

  • 14. Phosphorylated EGFR expression may predict outcome of EGFR-TKIs therapy for the advanced NSCLC patients with wild-type EGFR.
    Wang F; Wang S; Wang Z; Duan J; An T; Zhao J; Bai H; Wang J;
    J Exp Clin Cancer Res; 2012 Aug; 31(1):65. PubMed ID: 22901364
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intracranial Activity of Gefitinib and Capmatinib in a Patient with Previously Treated Non-Small Cell Lung Cancer Harboring a Concurrent EGFR Mutation and MET Amplification.
    Gainor JF; Stevens SE; Willers H; Shih HA; Heist RS
    J Thorac Oncol; 2020 Jan; 15(1):e8-e10. PubMed ID: 31864558
    [No Abstract]   [Full Text] [Related]  

  • 16. [Clinical effect of icotinib in treatment of elderly advanced non-small cell lung cancer patients with EGFR mutations].
    Ren YL; Sheng J; Zhou XY; Fang Y; Pan HM
    Zhonghua Zhong Liu Za Zhi; 2019 Feb; 41(2):152-153. PubMed ID: 30862147
    [No Abstract]   [Full Text] [Related]  

  • 17. Heterogeneity of EGFR-mutant clones and PD-L1 highly expressing clones affects treatment efficacy of EGFR-TKI and PD-1 inhibitor.
    Kunimasa K; Nakamura H; Sakai K; Kimura M; Inoue T; Tamiya M; Nishino K; Kumagai T; Nakatsuka S; Endo H; Inoue M; Nishio K; Imamura F
    Ann Oncol; 2018 Oct; 29(10):2145-2147. PubMed ID: 30099497
    [No Abstract]   [Full Text] [Related]  

  • 18. [Resistant mechanism and treatment strategy of tyrosine kinase inhibitors].
    Qiao J; Chen W
    Zhongguo Fei Ai Za Zhi; 2011 Oct; 14(10):806-10. PubMed ID: 22008111
    [No Abstract]   [Full Text] [Related]  

  • 19. [Toxicity associated with EGRF inhibition: review and key aspects in the management of afatinib].
    Taus Á
    Med Clin (Barc); 2016 Apr; 146 Suppl 1():30-5. PubMed ID: 27426246
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Time for molecularly targeted maintenance therapy for non-small-cell lung cancer?
    Stinchcombe TE; Ramalingam SS
    Lancet Oncol; 2010 Jun; 11(6):500-1. PubMed ID: 20493770
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.